Merck Income Taxes 2010-2024 | MRK

Merck annual/quarterly income taxes history and growth rate from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
  • Merck income taxes for the quarter ending September 30, 2024 were $0.929B, a 6.78% increase year-over-year.
  • Merck income taxes for the twelve months ending September 30, 2024 were $1.557B, a 44.94% decline year-over-year.
  • Merck annual income taxes for 2023 were $1.512B, a 21.17% decline from 2022.
  • Merck annual income taxes for 2022 were $1.918B, a 26.1% increase from 2021.
  • Merck annual income taxes for 2021 were $1.521B, a 13.51% increase from 2020.
Merck Annual Income Taxes
(Millions of US $)
2023 $1,512
2022 $1,918
2021 $1,521
2020 $1,340
2019 $1,565
2018 $2,508
2017 $4,103
2016 $718
2015 $942
2014 $5,349
2013 $1,028
2012 $2,440
2011 $942
2010 $671
2009 $2,268
Merck Quarterly Income Taxes
(Millions of US $)
2024-09-30 $929
2024-06-30 $545
2024-03-31 $903
2023-12-31 $-820
2023-09-30 $870
2023-06-30 $637
2023-03-31 $825
2022-12-31 $496
2022-09-30 $330
2022-06-30 $538
2022-03-31 $554
2021-12-31 $85
2021-09-30 $695
2021-06-30 $503
2021-03-31 $238
2020-12-31 $-55
2020-09-30 $380
2020-06-30 $396
2020-03-31 $619
2019-12-31 $305
2019-09-30 $440
2019-06-30 $615
2019-03-31 $205
2018-12-31 $827
2018-09-30 $707
2018-06-30 $370
2018-03-31 $604
2017-12-31 $2,917
2017-09-30 $251
2017-06-30 $488
2017-03-31 $447
2016-12-31 $-770
2016-09-30 $699
2016-06-30 $295
2016-03-31 $494
2015-12-31 $-166
2015-09-30 $566
2015-06-30 $119
2015-03-31 $423
2014-12-31 $4,483
2014-09-30 $648
2014-06-30 $-142
2014-03-31 $360
2013-12-31 $409
2013-09-30 $375
2013-06-30 $310
2013-03-31 $-66
2012-12-31 $385
2012-09-30 $455
2012-06-30 $860
2012-03-31 $740
2011-12-31 $38
2011-09-30 $628
2011-06-30 $-382
2011-03-31 $658
2010-12-31 $-202
2010-09-30 $126
2010-06-30 $461
2010-03-31 $286
2009-12-31 $-60
2009-09-30 $1,622
2009-06-30 $379
2009-03-31 $327
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $254.810B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $790.248B 81.85
Novo Nordisk (NVO) Denmark $489.545B 35.30
Johnson & Johnson (JNJ) United States $373.278B 15.14
AbbVie (ABBV) United States $308.242B 16.23
Novartis AG (NVS) Switzerland $215.989B 14.36
AstraZeneca (AZN) United Kingdom $200.887B 17.90
Pfizer (PFE) United States $148.702B 10.17
Sanofi (SNY) $128.465B 11.64
Innoviva (INVA) United States $1.259B 10.48